Prediction of the Possibility of Hemorrhagic Syndrome during Combined Antiplatelet Therapy According to the Krasnodar Region Registry

Background. According to the literature data, acute coronary syndrome (ACS) in 2-20 % of cases is combined with atrial fibrillation (AF). According to the current guidelines of the European Society of Cardiology (ESC), patients with coexisting AF and ACS should receive dual antiplatelet therapy for...

Full description

Bibliographic Details
Main Authors: Z. G. Tatarintseva, E. D. Kosmacheva, S. V. Kruchinova, V. A. Akinshina, A. A. Khalafyan
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2019-11-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
Online Access:https://www.rpcardio.com/jour/article/view/2041